当前位置: 首页 >> 检索结果
1. Multicentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (PURPLE Trial).
作者: Jan Drews.;Markus Zachäus.;Tobias Kleemann.;Jörg Schirra.;Oscar Cahyadi.;Oliver Möschler.;Christian Schulze.;Ingo Steinbrück.;Edris Wedi.;Oliver Pech.;Tobias J Weismüller.;Armin Küllmer.;Mohamed Abdelhafez.;Jochen Wedemeyer.;Torsten Beyna.;Julian Riedel.;Ulrich Paul Halm.;Carola Güther.;Riccardo Vasapolli.;Christian Torres Reyes.;Daniel R Quast.;Oliver Bachmann.;Erini Dedonaki.;Jörg Ulrich.;Inna Marchuk.;Christina Frahm.;Tanja Steffen.;Peter Wohlmuth.;Torsten Bunde.;Nele Geßler.;Thomas von Hahn.
来源: Gut. 2025年74卷7期1103-1111页
Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR).
2. Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
作者: Javier P Gisbert.;María G Donday.;Sabino Riestra.;Alfredo J Lucendo.;José-Manuel Benítez.;Mercè Navarro-Llavat.;Jesús Barrio.;Víctor J Morales-Alvarado.;Montserrat Rivero.;David Busquets.;Eduardo Leo Carnerero.;Olga Merino.;Óscar Nantes Castillejo.;Pablo Navarro.;Manuel Van Domselaar.;Ana Gutiérrez.;Inmaculada Alonso-Abreu.;Rafael Mejuto.;Luis Fernández-Salazar.;Marisa Iborra.;María Dolores Martín-Arranz.;Juan Ramón Pineda.;Manuela Josefa Sampedro.;Katja Serra Nilsson.;Abdel Bouhmidi.;Lissette Batista.;Carmen Muñoz Villafranca.;Iago Rodríguez-Lago.;Daniel Ceballos.;Iván Guerra.;Miriam Mañosa.;Ignacio Marín Jiménez.;Emilio Torrella.;Maribel Vera Mendoza.;María José Casanova.;Ruth de Francisco.;Laura Arias-González.;Sandra Marín Pedrosa.;Orlando García-Bosch.;Francisco Javier García-Alonso.;Pedro Delgado-Guillena.;María José García.;Leyanira Torrealba.;Andrea Núñez-Ortiz.;Miren Vicuña Arregui.;Marta Maia Bosca-Watts.;Isabel Blázquez.;Diana Acosta.;Ana Garre.;Montse Baldán.;Concepción Martínez.;Manuel Barreiro-de Acosta.;Eugeni Domènech.;Maria Esteve.;Valle García-Sánchez.;Pilar Nos.;Julián Panés.;María Chaparro.; .
来源: Gut. 2025年74卷3期387-396页
Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it.
3. Combined MRI, high-resolution manometry and a randomised trial of bisacodyl versus hyoscine show the significance of an enlarged colon in constipation: the RECLAIM study.
作者: Victoria Wilkinson-Smith.;Mark Scott.;Alex Menys.;Lukasz Wiklendt.;Luca Marciani.;David Atkinson.;Stefano Sansone.;Ausra Zdanaviciene.;Carol Coupland.;Charles H Knowles.;Philip Dinning.;Stuart A Taylor.;Penny Gowland.;Caroline Louise Hoad.;Maura Corsetti.;Robin C Spiller.
来源: Gut. 2024年74卷1期35-44页
Colonic motility in constipation can be assessed non-invasively using MRI.
4. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
作者: Nicolas Pierre.;Vân Anh Huynh-Thu.;Dominique Baiwir.;Gabriel Mazzucchelli.;Maximilien Fléron.;Lisette Trzpiot.;Gauthier Eppe.;Edwin De Pauw.;David Laharie.;Jack Satsangi.;Peter Bossuyt.;Lucine Vuitton.;Sophie Vieujean.;Jean-Frédéric Colombel.;Marie-Alice Meuwis.;Edouard Louis.; .
来源: Gut. 2024年73卷12期1965-1973页
In patients with Crohn's disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (≤6 months) and mid/long-term relapse (>6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy).
5. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
作者: Andrea Vecchi.;Marzia Rossi.;Camilla Tiezzi.;Paola Fisicaro.;Sara Doselli.;Elena Adelina Gabor.;Amalia Penna.;Ilaria Montali.;Camilla Ceccatelli Berti.;Valentina Reverberi.;Anna Montali.;Simon P Fletcher.;Elisabetta Degasperi.;Dana Sambarino.;Diletta Laccabue.;Floriana Facchetti.;Simona Schivazappa.;Elisabetta Loggi.;Barbara Coco.;Daniela Cavallone.;Elena Rosselli Del Turco.;Marco Massari.;Giuseppe Pedrazzi.;Gabriele Missale.;Gabriella Verucchi.;Pietro Andreone.;Maurizia Rossana Brunetto.;Pietro Lampertico.;Carlo Ferrari.;Carolina Boni.
来源: Gut. 2024年73卷10期1737-1748页
Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-α on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-α for a tailored application of IFN-α add-on.
6. Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy.
作者: Wen Gao.;Jianxiang Liu.;Xiaolei Wang.;Jingwen Li.;Xuezhi Zhang.;Hui Ye.;Jiang Li.;Xinhong Dong.;Binbin Liu.;Chi Wang.;Ying Xu.;Guigen Teng.;Yuling Tian.;Jinpei Dong.;Chaoyi Ge.;Hong Cheng.
来源: Gut. 2024年73卷9期1414-1420页
This study aimed to evaluate the efficacy and safety of vonoprazan and tetracycline (VT) dual therapy as first-line treatment for Helicobacter pylori infection in patients with penicillin allergy.
7. Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study).
作者: Iain Robert Louis Kean.;John A Clark.;Zhenguang Zhang.;Esther Daubney.;Deborah White.;Paloma Ferrando-Vivas.;Gema Milla.;Brian Cuthbertson.;John Pappachan.;Nigel Klein.;Paul Mouncey.;Kathy Rowan.;John Myburgh.;Theodore Gouliouris.;Stephen Baker.;Julian Parkhill.;Nazima Pathan.; Arctic Research Team.
来源: Gut. 2024年73卷6期910-921页
Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resistance (AMR) gene profiles in critically ill children treated with SDD-enhanced infection control compared with conventional infection control.
8. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial.
作者: Jiaying Zhu.;Chuqing Sun.;Min Li.;Guoru Hu.;Xing-Ming Zhao.;Wei-Hua Chen.
来源: Gut. 2024年73卷7期1087-1097页
We aim to compare the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on the gut microbiota through longitudinal analysis.
9. Prebiotic diet changes neural correlates of food decision-making in overweight adults: a randomised controlled within-subject cross-over trial.
作者: Evelyn Medawar.;Frauke Beyer.;Ronja Thieleking.;Sven-Bastiaan Haange.;Ulrike Rolle-Kampczyk.;Madlen Reinicke.;Rima Chakaroun.;Martin von Bergen.;Michael Stumvoll.;Arno Villringer.;A Veronica Witte.
来源: Gut. 2024年73卷2期298-310页
Animal studies suggest that prebiotic, plant-derived nutrients could improve homoeostatic and hedonic brain functions through improvements in microbiome-gut-brain communication. However, little is known if these results are applicable to humans. Therefore, we tested the effects of high-dosed prebiotic fibre on reward-related food decision-making in a randomised controlled within-subject cross-over study and assayed potential microbial and metabolic markers.
10. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
作者: Xinrong Zhang.;Terry Cheuk-Fung Yip.;Grace Lai-Hung Wong.;Wei-Xuan Leow.;Lilian Yan Liang.;Lee-Ling Lim.;Guanlin Li.;Luqman Ibrahim.;Huapeng Lin.;Jimmy Che To Lai.;Angel Mei-Ling Chim.;Henry Lik Yuen Chan.;Alice Pik-Shan Kong.;Wah Kheong Chan.;Vincent Wai-Sun Wong.
来源: Gut. 2023年72卷12期2364-2371页
We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase the detection of advanced liver disease in patients with type 2 diabetes.
11. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
作者: Evan S Dellon.;Kathryn A Peterson.;Benjamin L Mitlyng.;Alina Iuga.;Christine E Bookhout.;Lindsay M Cortright.;Kacie B Walker.;Timothy S Gee.;Sarah J McGee.;Brenderia A Cameron.;Joseph A Galanko.;John T Woosley.;Swathi Eluri.;Susan E Moist.;Ikuo Hirano.
来源: Gut. 2023年72卷10期1828-1837页
We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in eosinophilic oesophagitis (EoE).
12. Gut microbiome modulates the effects of a personalised postprandial-targeting (PPT) diet on cardiometabolic markers: a diet intervention in pre-diabetes.
作者: Orly Ben-Yacov.;Anastasia Godneva.;Michal Rein.;Smadar Shilo.;Maya Lotan-Pompan.;Adina Weinberger.;Eran Segal.
来源: Gut. 2023年72卷8期1486-1496页
To explore the interplay between dietary modifications, microbiome composition and host metabolic responses in a dietary intervention setting of a personalised postprandial-targeting (PPT) diet versus a Mediterranean (MED) diet in pre-diabetes.
13. Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial.
作者: Ji Young Bang.;Nirag Jhala.;Anjali Seth.;Konrad Krall.;Udayakumar Navaneethan.;Robert Hawes.;Charles Melbern Wilcox.;Shyam Varadarajulu.
来源: Gut. 2023年72卷7期1255-1257页 14. Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.
作者: Frank Wagner.;John C Mansfield.;Annemarie N Lekkerkerker.;Yehong Wang.;Mary Keir.;Ajit Dash.;Brandon Butcher.;Brandon Harder.;Luz D Orozco.;Jordan S Mar.;Hao Chen.;Michael E Rothenberg.
来源: Gut. 2023年72卷8期1451-1461页
The interleukin-22 cytokine (IL-22) has demonstrated efficacy in preclinical colitis models with non-immunosuppressive mechanism of action. Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist that links IL-22 to the crystallisable fragment (Fc) of human IgG4 for improved pharmacokinetic characteristics, but with a mutation to minimise Fc effector functions.
15. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
作者: Harry L A Janssen.;Jinlin Hou.;Tarik Asselah.;Henry L Y Chan.;Fabien Zoulim.;Yasuhito Tanaka.;Ewa Janczewska.;Ronald G Nahass.;Stefan Bourgeois.;Maria Buti.;Pietro Lampertico.;Oliver Lenz.;Thierry Verbinnen.;Joris Vandenbossche.;Willem Talloen.;Ronald Kalmeijer.;Maria Beumont.;Michael Biermer.;Umesh Shukla.
来源: Gut. 2023年72卷7期1385-1398页
We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier: NCT03361956).
16. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
作者: Heinz Zoller.;Myles Wolf.;Irina Blumenstein.;Christian Primas.;Stefan Lindgren.;Lars L Thomsen.;Walter Reinisch.;Tariq Iqbal.
来源: Gut. 2023年72卷4期644-653页
Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)-can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or ferric derisomaltose (FDI).
17. Use of over-the-scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-labelled, multicentre international randomised controlled trial.
作者: Shannon Chan.;Rapat Pittayanon.;Hsiu-Po Wang.;Jiann-Hwa Chen.;Anthony Yb Teoh.;Yu Ting Kuo.;Raymond Sy Tang.;Hon Chi Yip.;Stephen Ka Kei Ng.;Sunny Wong.;Joyce Wing Yan Mak.;Heyson Chan.;Louis Lau.;Rashid N Lui.;Marc Wong.;Rungsun Rerknimitr.;Enders K Ng.;Philip Wai Yan Chiu.
来源: Gut. 2023年72卷4期638-643页
Over-the-scope clip (OTSC) has been used recently for primary haemostasis of peptic ulcers. This study aimed to compare the efficacy of OTSC to standard endoscopic therapy in primary treatment of patients with peptic ulcer bleeding that are of size ≥1.5 cm. The target population accounts for only 2.5% of all upper GI bleeders.
18. Effect of endoscopic sleeve gastroplasty on gastric emptying, motility and hormones: a comparative prospective study.
作者: Eric J Vargas.;Monika Rizk.;Jacky Gomez-Villa.;Phillip K Edwards.;Veeravich Jaruvongvanich.;Andrew C Storm.;Andres Acosta.;David Lake.;Jeff Fidler.;Adil E Bharucha.;Michael Camilleri.;Barham K Abu Dayyeh.
来源: Gut. 2023年72卷6期1073-1080页
Endoscopic sleeve gastroplasty (ESG) has gained global adoption but our understanding of its mechanism(s) of action and durability of efficacy is limited. We sought to determine changes in gastric emptying (GE), gastric motility (GM), hormones and eating behaviours after ESG.
19. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
作者: Carol Angela Howell.;Anu Kemppinen.;Victoria Allgar.;Matthew Dodd.;Charles H Knowles.;John McLaughlin.;Preeti Pandya.;Peter Whorwell.;Elena Markaryan.;Yan Yiannakou.
来源: Gut. 2022年71卷12期2430-2438页
Irritable bowel syndrome with diarrhoea (IBS-D) is a common and challenging condition that significantly reduces quality of life. Enterosgel (polymethylsiloxane polyhydrate) is an intestinal adsorbent which sequesters harmful molecules and is safe and effective in acute infective diarrhoea. This randomised controlled multicentre trial aimed to investigate its safety and efficacy in patients with IBS-D.
20. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute.
作者: Florencia Carbone.;Karen Van den Houte.;Linde Besard.;Céline Tack.;Joris Arts.;Philip Caenepeel.;Hubert Piessevaux.;Alain Vandenberghe.;Christophe Matthys.;Jessica Biesiekierski.;Luc Capiau.;Steven Ceulemans.;Olivier Gernay.;Lydia Jones.;Sophie Maes.;Christian Peetermans.;Willem Raat.;Jeroen Stubbe.;Rudy Van Boxstael.;Olivia Vandeput.;Sophie Van Steenbergen.;Lukas Van Oudenhove.;Tim Vanuytsel.;Michael Jones.;Jan Tack.; .; .
来源: Gut. 2022年71卷11期2226-2232页
In Europe, IBS is commonly treated with musculotropic spasmolytics (eg, otilonium bromide, OB). In tertiary care, a low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet provides significant improvement. Yet, dietary treatment remains to be explored in primary care. We evaluated the effect of a smartphone FODMAP-lowering diet application versus OB on symptoms in primary care IBS.
|